Metastatic cancer treatment using abscopal effect with radiotherapy
Summary
The USPTO published patent application US20260091085A1 assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising type 1 interferon combined with low-dose radiotherapy to induce systemic anticancer effects (abscopal effect) in metastatic cancer sites. The application claims a method where administering type 1 interferon with low-dose radiation to the primary tumor site produces anticancer effects at non-radiated metastatic sites.
What changed
USPTO published patent application US20260091085A1 (filed September 2, 2025) claiming a composition for treating metastatic cancer using type 1 interferon combined with low-dose radiotherapy to induce an abscopal effect. The invention demonstrates that while low-dose radiation alone to the primary cancer site does not produce systemic anticancer effects, combining type 1 interferon with low-dose radiation generates anticancer activity at distant metastatic sites not directly irradiated. The composition comprises type 1 interferon as an active therapeutic agent or adjuvant for metastatic cancer treatment.
This is a patent application publication, not a regulatory requirement. Pharmaceutical companies, cancer treatment researchers, and healthcare providers involved in oncology therapeutics may review the disclosed composition and methods for competitive intelligence, research planning, or freedom-to-operate analysis. No compliance actions or deadlines are associated with this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR SYSTEMIC ANTICANCER TREATMENT IN LOCALIZED RADIOTHERAPY
Application US20260091085A1 Kind: A1 Apr 02, 2026
Assignee
INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors
Sae Gwang PARK, Jin Hee PARK
Abstract
The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.
CPC Classifications
A61K 38/215 A61N 5/10 A61P 35/00 C07K 16/2818 C07K 16/2827 A61N 2005/1092
Filing Date
2025-09-02
Application No.
19317066
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.